Does vitamin C prevent the common cold?

Evelyn Gómez^{a,b}, Sebastián Quidel^{a,b}, Gonzalo Bravo-Soto^{b,d}, Ángela Ortigoza^{b,c}

^a Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

^b Proyecto Epistemonikos, Santiago, Chile

^c Departamento de Medicina Familiar, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile ^d Centro Evidencia UC, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

*Corresponding author acortigoza@uc.cl

Citation Gómez E, Quidel S, Bravo-Soto GA, Ortigoza A. Does vitamin C prevent the common cold?. *Medwave* 2018 Jul-Ago;18(4):e7236

Doi 10.5867/medwave.2018.04.7236

Submission date 13/3/2018 Acceptance date 1/8/2018 Publication date 6/8/2018

Origin This article is a product of the Evidence Synthesis Project of Epistemonikos Fundation, in collaboration with Medwave for its publication

Type of review Non-blinded peer review by members of the methodological team of Epistemonikos Evidence Synthesis Project Potential conflicts of interest The authors do not have relevant interests to declare.

Abstract

Introduction

The common cold is one of the most common diseases. It is generally believed that the consumption of vitamin C prevents its appearance, but the actual efficacy of this measure is controversial.

Methods

To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach.

Results and conclusions

We identified eight systematic reviews including 45 studies overall, of which 31 were randomized trials. We concluded the consumption of vitamin C does not prevent the incidence of common cold.

Problem

The common cold is one of the most common diseases in the general population. The term "common cold" does not refer to a specific condition, but to a group of symptoms such as nasal obstruction, sore throat, cough, lethargy and asthenia, with or without fever. These symptoms have multiple etiological agents such as rhinovirus, adenovirus, syncytial virus, etc. Despite the benign nature of this disease, it leads to a substantive economic burden in terms of medical consultation, treatment, and work or school absentee-ism¹.

On the other hand, effective alternatives to prevent this condition are not available, and the efforts to develop a vaccine have been fruitless.

Vitamin C is usually perceived as an effective, harmless and inexpensive therapeutic alternative. Its use began in the early 30s and in the 70s it became widespread when the Nobel Prize winner, Linus Pauling, concluded that the use of vitamin C could prevent and relieve the common cold¹. It is thought that vitamin C could improve the functioning of the immune system through various mechanisms²: phagocytes and lymphocytes concentrate vitamin C in levels up to 100 times higher than plasma, suggesting it has a



role in the immune system; vitamin C increases the response of T lymphocytes and interferon levels. However, although the effects on the immune system are well reported, it is not clear whether the intake of vitamin C for the prevention of the common cold translates into a clinically relevant benefit.

Key messages

• The consumption of vitamin C does not prevent the incidence of common cold.

About the body of evidence for this question

What is the evidence. See evidence matrix in Epistemonikos later	We found eight systematic reviews ²⁻⁹ that included 45 primary studies reported in 43 references ¹⁰⁻⁵² , of which 31 corresponded to randomized controlled trials reported on 30 references ¹⁰⁻³⁹ .
	Three trials ^{14,33,38} and the subgroups of five tri- als ^{10,23,30,32,37} were excluded from the analysis because they did not refer to our population of interest. We also excluded four trials ^{13,15,35,39} that used low-dose vitamin C as a placebo.
	This table and the summary in general are based on the relevant randomized trials. We excluded observa- tional studies because they did not increase the cer- tainty of the existing evidence or provide additional relevant information.
What types of patients were included*	The trials evaluated adults and children. Eighteen tri- als ^{10,12,17-37} included adults and four trials included children ^{16,25,26,31} . One trial ¹⁰ included participants be- tween 14-64 years.
	In general, the trials did not report the season when they were conducted and did not provide a clear defi- nition of common cold, which is based on combina- tion of symptoms such as nasal discharge, sore throat, lethargy and discomfort, with or without fever.
What types of interven- tions were included*	All trials evaluated supplementation with oral doses higher than 0.08 g/day of vitamin C.
	Nine trials ^{10,17,18,22,31,32,34,36,37} administered low dose of vitamin C, in a range of 0.08 to 0.6 g/day. Ten trials 1 g/day ^{11,12,19,20,23,25,26,28,29,30} , four trials 2 g/day [16,21,24,38] and one trial 3 g/day ²⁷ .
	All trials compared against placebo.
What types of outcomes were measured	The different trials measured multiple outcomes such, which were pooled by the systematic reviews as fol- lows: incidence, duration and severity of the cold, among others.
	The follow-up period ranged from 3 weeks to 36 weeks.

* The information about primary studies is extracted from the systematic reviews identified, unless otherwise specified.

Methods

To answer the question, we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others, to identify systematic reviews and their included primary studies. We extracted data from the identified reviews and reanalyzed data from primary studies included in those reviews. With this information, we generated a structured summary denominated FRISBEE (Friendly Summary of Body of Evidence using Epistemonikos) using a pre-established format, which includes key messages, a summary of the body of evidence (presented as an evidence matrix in Epistemonikos), meta-analysis of the total of studies when it is possible, a summary of table findings following the GRADE approach and a table of other considerations for decisionmaking.

Summary of Findings

The information of the effects of vitamin C in the prevention of common cold is based on 18 randomized trials^{10,12,16,17,19-22,24-26,28-30,32,34,36,37}, which include 8472 patients in total. All trials measured the incidence of common cold during a specific time interval (8,472 patients).

The summary of findings is as follows:

• The consumption of vitamin C does not prevent the incidence of common cold. The certainty of the evidence is high.

Vitamin C to prevent the common cold				
Healthy patients, adults and children Vitamin C in doses greater than 0.08 g/day Placebo				
Absolute effect*			Certainty of	
WITHOUT vitamin C	WITHvitamin C	Relative effect (95% CI)	evidence	
Difference: patients per 1000		())/()())	(GRADE)	
487 per 1000	473 per 1000	BR 0.97	ወወወ	
Difference: 15 patients less (Margin of error: 5 less to 39 more)		(0.92 to 1.01)	⊕⊕⊕⊕ High	
Margin of error: 95% confidence interval (CI). RR: Risk ratio. GRADE: Evidence grades of the GRADE Working Group (see later). *The risk WITHOUT vitamin C is based on the risk in the control group of the trials. The risk WITH vitamin C (and its margin of error) is calculated from relative effect (and its margin of error).				
	Healthy patients, adults a Vitamin C in doses great Placebo Mbsolute e WITHOUT vitamin C Difference: patier 487 per 1000 Difference: 15 p (Margin of error: 5 onfidence interval (CI). les of the GRADE Working G vitamin C is based on the risk i	Healthy patients, adults and children Vitamin C in doses greater than 0.08 g/day Placebo Absolute effect* WITHOUT vitamin C WITHvitamin C Difference: patients per 1000 487 per 1000 473 per 1000 Difference: 15 patients less (Margin of error: 5 less to 39 more) onfidence interval (CI). les of the GRADE Working Group (see later). vitamin C is based on the risk in the control group of the second	Healthy patients, adults and children Vitamin C in doses greater than 0.08 g/day Placebo Absolute effect* WITHOUT vitamin C WITHvitamin C Difference: patients per 1000 487 per 1000 473 per 1000 RR 0.97 Difference: 15 patients less (Margin of error: 5 less to 39 more) RR 0.97 (0.92 to 1.01) confidence interval (CI). les of the GRADE Working Group (see later). vitamin C is based on the risk in the control group of the trials. The risk WITH	

Following the link to access the interactive version of this table (Interactive Summary of Findings - iSoF)



About the certainty of the evidence

(GRADE)*

$\oplus \oplus \oplus \oplus$

High: This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different[†] is low.

$\oplus \oplus \oplus \bigcirc \bigcirc$

Moderate: This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different[†] is moderate.

$\oplus \oplus \bigcirc \bigcirc$

Low: This research provides some indication of the likely effect. However, the likelihood that it will be substantially different† is high.

$\oplus OOO$

Very low: This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different[†] is very high.

* This concept is also called 'quality of the evidence' or 'confidence in effect estimates'.

† Substantially different = a large enough difference that it might affect a decision

Other considerations for decision-making

To whom this evidence does and does not apply

These results apply to healthy population in general, both adult and children. Although the trials did not evaluate patients with specific comorbidities, in the absence of direct evidence, it is reasonable to extrapolate this evidence to these populations.

This evidence does not apply to high performance athletes or other people subjected to major physical stress, since they are considered a different population, in which the etiology of cold symptoms responds to other mechanisms, not related to viral contagion.

About the outcomes included in this summary

The outcome selected for the summary of findings table is the only one considered critical for decision-making according to the opinion of the authors of this summary, which agrees with the systematic reviews analyzed.

Balance between benefits and risks, and certainty of the evidence

Although it is an intervention that has none or minimal adverse effects,, as there is no benefit, the balance between benefits and risks is not favorable.

Resource considerations

Vitamin C is relatively inexpensive but has no benefit, so the balance between benefits and costs is not favorable.

From a population perspective, the expenses incurred to prevent the common cold by consuming vitamin C are large.

What would patients and their doctors think about this intervention

Faced with the evidence presented in this summary, both clinicians and patients should lean against using vitamin C for the prevention of the common cold.

However, it might be difficult to make patients desist from such deep-rooted preconceived ideas, even considering the certainty of the evidence. Therefore, variability in the decision-making is to be expected.

It is key for physicians to be reassured by scientific evidence in order to persuade their patients that this popular treatment offers no benefit.

Differences between this summary and other sources

The conclusions of this summary coincide with those of the systematic reviews identified.

These results agree with those reported in the American Family Physician guideline⁵³, which rely on the results of the Cochrane systematic review⁴ to back their conclusions.

Could this evidence change in the future?


It is unlikely that the appearance of new evidence could modify the conclusions of this summary, due to the high certainty of the existing evidence.

In addition, we did not identify ongoing randomized trials evaluating this question in the International Clinical Trials Registry Platform of the World Health Organization, or ongoing systematic reviews in PROSPERO database.



How we conducted this summary

Using automated and collaborative means, we compiled all the relevant evidence for the question of interest and we present it as a matrix of evidence.



An evidence matrix is a table that compares systematic reviews that answer the same question.

Rows represent systematic reviews, and columns show primary studies. The boxes in green correspond to studies included in the respective revisions. The system automatically detects new systematic reviews including any of the primary studies in the matrix, which will be added if they actually answer the same question.

Follow the link to access the interactive version: <u>Vitamina C for the preven-</u> tion of common cold

Referencias

- 1. Heikkinen T1, Järvinen A. The common cold. Lancet. 2003 Jan 4;361(9351):51-9.
- Hemilä H. Vitamin C intake and susceptibility to the common cold. Br J Nutr. 1997 Jan;77(1):59-72. | <u>PubMed</u> |
- Hemilä H. Vitamin C and common cold incidence: a review of studies with subjects under heavy physical stress. Int J Sports Med. 1996 Jul;17(5):379-83. | <u>PubMed</u> |
- Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013 Jan 31;(1): CD000980.
 CrossRef | PubMed |
- Hemilä H. Vitamin C supplementation and common cold symptoms: factors affecting the magnitude of the benefit. Med Hypotheses. 1999 Feb;52(2):171-8 | <u>PubMed</u> |
- Hemilä H. Vitamin C supplementation and respiratory infections: a systematic review. Mil Med. 2004 Nov;169(11):920-5. Review. |<u>Pub-Med</u>|
- Chalmers TC. Effects of ascorbic acid on the common cold. An evaluation of the evidence. Am J Med. 1975 Apr;58(4):532-6. Review. <u>PubMed</u>
- Pauling L. The significance of the evidence about ascorbic acid and the common cold. Proc Natl Acad Sci U S A. 1971 Nov;68(11):2678-81. Review. | <u>PubMed</u> | <u>PMC</u> |
- 9. Truswell S. Ascorbic Acid. New England Journal of Medicin. 1986
- Peters EM, Goetzsche JM, Grobbelaar B, Noakes TD. Vitamin Csupplementation reduces the incidence of postrace symptoms of upperrespiratory-tract infection in ultramarathon runners. Am J Clin Nutr. 1993 Feb;57(2):170-4. | <u>PubMed</u> |

Notes

The upper portion of the matrix of evidence will display a warning of "new evidence" if new systematic reviews are published after the publication of this summary. Even though the project considers the periodical update of these summaries, users are invited to comment in *Medwave* or to contact the authors through email if they find new evidence and the summary should be updated earlier.

After creating an account in Epistemonikos, users will be able to save the matrixes and to receive automated notifications any time new evidence potentially relevant for the question appears.

This article is part of the Epistemonikos Evidence Synthesis project. It is elaborated with a pre-established methodology, following rigorous methodological standards and internal peer review process. Each of these articles corresponds to a summary, denominated FRISBEE (Friendly Summary of Body of Evidence using Epistemonikos), whose main objective is to synthesize the body of evidence for a specific question, with a friendly format to clinical professionals. Its main resources are based on the evidence matrix of Epistemonikos and analysis of results using GRADE methodology. Further details of the methods for developing this FRISBEE are described here (http://dx.doi.org/10.5867/medwave.2014.06.5997)

Epistemonikos foundation is a non-for-profit organization aiming to bring information closer to health decision-makers with technology. Its main development is Epistemonikos database

www.epistemonikos.org.

- Carr AB, Einstein R, Lai LY, Martin NG, Starmer GA. Vitamin C and the common cold: using identical twins as controls. Med J Aust. 1981 Oct 17;2(8):411-2. | <u>PubMed</u> |
- Anderson TW, Reid DB, Beaton GH. Vitamin C and the common cold: a double-blind trial. Can Med Assoc J. 1972 Sep 23;107(6):503-8. | PubMed | PMC |
- Miller JZ, Nance WE, Norton JA, Wolen RL, Griffith RS, Rose RJ. Therapeutic effect of vitamin C. A co-twin control study. JAMA. 1977 Jan 17;237(3):248-51. | <u>PubMed</u> |
- RITZEL G. [Critical evaluation of vitamin C as a prophylactic and therapeutic agent in colds]. Helv Med Acta. 1961 Jan;28:63-8. German. | <u>PubMed</u> |
- Ludvigsson J, Hansson LO, Tibbling G. Vitamin C as a preventive medicine against common colds in children. Scand J Infect Dis. 1977;9(2):91-8. | <u>PubMed</u> |
- Bancalari A, Seguel C, Neira F, Ruíz I, Calvo C. [Prophylactic value of vitamin C in acute respiratory tract infections in schoolchildren]. Rev Med Chil. 1984 Sep;112(9):871-6. Spanish. | <u>PubMed</u> |
- 17. Baird IM, Hughes RE, Wilson HK, Davies JE, Howard AN. The effects of ascorbic acid and flavonoids on the occurrence of symptoms

MEDave

normally associated with the common cold. Am J Clin Nutr. 1979 Aug;32(8):1686-90. | <u>PubMed</u> |

- Anderson TW, Beaton GH, Corey P, Spero L. Winter illness and vitamin C: the effect of relatively low doses. Can Med Assoc J. 1975 Apr 5;112(7):823-6. | <u>PubMed</u> | <u>PMC</u> |
- Elwood PC, Lee HP, St Leger AS, Baird M, Howard AN. A randomized controlled trial of vitamin C in the prevention and amelioration of the common cold. Br J Prev Soc Med. 1976 Sep;30(3):193-6. <u>Pub-Med</u> <u>PMC</u>
- Carson M, Corbett M, Cox H, Pollitt N. Letter: Vitamin C and the common cold. Br Med J. 1974 Mar 23;1(5907):577. | <u>PubMed</u> | <u>PMC</u> |
- Liljefors I. [Vitamin C and the common cold]. Lakartidningen. 1972 Jul 5;69(28):3304-5. Swedish. | <u>PubMed</u> |
- 22. FRANZ WL, HEYL HL, SANDS GW. Blood ascorbic acid level in bioflavonoid and ascorbic acid therapy of common cold. J Am Med Assoc. 1956 Nov 24;162(13):1224-6. | <u>PubMed</u> |
- Constantini NW, Dubnov-Raz G, Eyal BB, Berry EM, Cohen AH, Hemilä H. The effect of vitamin C on upper respiratory infections in adolescent swimmers: a randomized trial. Eur J Pediatr. 2011 Jan;170(1):59-63. CrossRef PubMed
- 24. Pitt HA, Costrini AM. Vitamin C prophylaxis in marine recruits. JAMA. 1979 Mar 2;241(9):908-11. | <u>PubMed</u> |
- 25. Coulehan JL, Eberhard S, Kapner L, Taylor F, Rogers K, Garry P. Vitamin C and acute illness in Navajo school children. N Engl J Med. 1976 Oct 28;295(18):973-7. | PubMed |
- 26. Clegg KM, Macdonald JM. L-Ascorbic acid and D-isoascorbic acid in a common cold survey. Am J Clin Nutr. 1975 Sep;28(9):973-6. | <u>Pub-Med</u> |
- 27. Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. Ascorbic acid for the common cold. A prophylactic and therapeutic trial. JAMA. 1975 Mar 10;231(10):1038-42. | <u>PubMed</u> |
- Anderson TW, Suranyi G, Beaton GH. The effect on winter illness of large doses of vitamin C. Can Med Assoc J. 1974 Jul 6;111(1):31-6.
 <u>PubMed</u> | <u>PMC</u> |
- 29. Van Straten M, Josling P. Preventing the common cold with a vitamin C supplement: a double-blind, placebo-controlled survey. Adv Ther. 2002 May-Jun;19(3):151-9. | <u>PubMed</u> |
- Himmelstein SA. The effect of vitamin C supplementation on incidence of upper respiratory tract infections in marathon runners [PhD Thesis; 163 pp]. Albuquerque, NM: University of New Mexico, 1996.
 Link |
- Wilson CW, Loh HS, Foster FG. The beneficial effect of vitamin C on the common cold. Eur J Clin Pharmacol. 1973 Jun;6(1):26-32.
 <u>PubMed</u>
- 32. Peters EM, Goetzsche JM, Joseph LE, Noakes TD. Vitamin C as effective as combinations of antioxidant nutrients in reducing symptoms of upper respiratory tract infection in ultramarathon runners. South African Journal of Sports Medicine 1996;11:23–7. | Link |
- Sabiston B. H., Radomski M. W.: Health Problems and Vitamin in Canadian Northern Military Operations. DCIEM Report No. 74-R-W12. Downsview, Ontario, Defence Research Board, 1974. | Link |
- Dahlberg G, Engel A, Rydin H. The value of ascorbic acid as a prophylactic against common colds. Acta Medica Scandinavica 1944;119:540–61. | Link |

- Sasazuki S, Sasaki S, Tsubono Y, Okubo S, Hayashi M, Tsugane S. Effect of vitamin C on common cold: randomized controlled trial. Eur J Clin Nutr. 2006 Jan;60(1):9-17. | <u>PubMed</u> |
- COWAN DW, DIEHL HS, BAKER AB. VItamins for the prevention of colds. Journal of the American Medical Association. 1942;120(16):1268-1271.
- Moolla ME. The effect of supplemental anti-oxidants on the incidence and severity of upper respiratory infections in Ultra Marathon runners [MSc thesis]. Cape Town, South Africa: University of Cape Town, 1996. | Link |
- Elliot B. Ascorbic acid: efficacy in the prevention of symptoms of respiratory infection on a Polaris submarine. IRCS Journal of the International Research Communications: Medical Science 1973;1(3):12.
 Link
- Briggs M. Vitamin C and infectious disease: a review of the literature and the results of a randomised double blind prospective study over eight years. In: Briggs MH editor (s). Recent Vitamin Research. Boca Raton, FL: CRC Press, 1984:39–82. | Link |
- Glazebrook AJ, Thomson S. The administration of vitamin C in a large institution and its effect on general health and resistance to infection. J Hyg (Lond). 1942 Jan;42(1):1-19. | <u>PubMed</u> | <u>PMC</u> |
- Coulehan JL, Reisinger KS, Rogers KD, Bradley DW. Vitamin C prophylaxis in a boarding school. N Engl J Med. 1974 Jan 3;290(1):6-10. | <u>PubMed</u> |
- Schwartz AR, Togo Y, Hornick RB, Tominaga S, Gleckman RA. Evaluation of the efficacy of ascorbic acid in prophylaxis of induced rhinovirus 44 infection in man. J Infect Dis. 1973 Oct;128(4):500-5. | <u>Pub-Med</u> |
- Regnier E. The administration of large doses of ascorbic acid in the prevention and treatment of the common cold. II. Rev Allergy. 1968 Oct;22(10):948-56. | <u>PubMed</u> |
- 44. Charleston SS, Clegg KM. Ascorbic acid and the common cold. Lancet. 1972 Jun 24;1(7765):1401-2. | <u>PubMed</u> |
- Walker GH, Bynoe ML, Tyrrell DA. Trial of ascorbic acid in prevention of colds. Br Med J. 1967 Mar 11;1(5540):603-6. | <u>PubMed</u> | <u>PMC</u> |
- NIEMI T. [Acute respiratory infections and vitamin C]. Duodecim. 1951;67(4):360-8. Undetermined Language. | <u>PubMed</u> |
- BESSEL-LORCK C. [Common cold prophylaxis in young people at a ski-camp]. Med Nov. 1959 Oct 31;44:2126-7. German. | <u>PubMed</u>
- BARNES FE Jr. Vitamin supplements and the incidence of colds in high school basketball players. A preliminary report. N C Med J. 1961 Jan;22:22-6. | <u>PubMed</u> |
- Gormly PJ. Megadosage of ascorbic acid in an Antarctic expedition. Br J Nutr. 1977 Mar;37(2):269-77. | <u>PubMed</u> |
- Dick EC, Mink KA, Olander D, Schult PA, Jennings LC, Inhorn SL. Amelioration of rhinovirus type 16 (RV 16) colds in ascorbic acid supplemented volunteers [abstract]. 30th ICAAC Proceedings. 1990.
- Scheunert VA. Adult requirements for vitamin C [Der Tagesbedarf des Erwachsenen an Vitamin C]. Internationale Zeitschrift für Vitaminforschung 1949;20:374–86. | Link |
- 52. WILSON, C. W. M.; LOH, H. S., Ascorbic acid and upper respiratory inflammation. Acta Allergologica. 1969.
- 53. Fashner J, Ericson K, Werner S. Treatment of the common cold in children and adults. American family physician. 2012.86(2).

Correspondencia a

Centro Evidencia UC Pontificia Universidad Católica de Chile Centro de Innovación UC Anacleto Angelini Avda.Vicuña Mackenna 4860 Macul Santiago Chile



Esta obra de Medwave está bajo una licencia Creative Commons Atribución-No Comercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

